Delayed Cutaneous Microvascular Responses With Non-consecutive 3 Days of Remote Ischemic Preconditioning

Jahyun Kim1, Warren D. Franke2 and James A. Lang2*

1 Department of Kinesiology, California State University, Bakersfield, Bakersfield, CA, United States, 2 Department of Kinesiology, Iowa State University, Ames, IA, United States

The optimal frequency and duration of remote ischemic preconditioning (RIPC) that augments microvascular function is unknown. A single bout of RIPC increases cutaneous endothelial function for ~48 h, whereas 1 week of daily RIPC bouts improves more sustained endothelium-independent function. We hypothesized that 3 days of RIPC separated by rest days (3QOD RIPC) would result in sustained increases in both endothelium-dependent and endothelium-independent functions. Cutaneous microvascular function was assessed in 13 healthy young participants (aged 20.5 ± 3.9 years; 5 males, 8 females) before 3QOD and then 24, 48, and 72 h and a week after 3QOD. RIPC consisted of four repetitions of 5 min of blood flow occlusion separated by 5 min of reperfusion. Skin blood flow responses to local heating (Tloc = 42°C), acetylcholine (Ach), and sodium nitroprusside (SNP) were measured using laser speckle contrast imaging and expressed as cutaneous vascular conductance (CVC = PU·mmHg⁻¹). Local heating-mediated vasodilation was increased 72 h after 3QOD and the increased responsivity persisted a week later (1.08 ± 0.24 vs. 1.34 ± 0.46, 1.21 ± 0.36 PU·mmHg⁻¹; ΔCVC, pre-RIPC vs. 72 h, a week after 3QOD; P = 0.054). Ach-induced cutaneous vasodilation increased a week after 3QOD (0.73 ± 0.41 vs. 0.95 ± 0.49 PU·mmHg⁻¹; ΔCVC, pre-RIPC vs. a week after 3QOD; P < 0.05). SNP-induced cutaneous vasodilation increased 24 h after 3QOD (0.47 ± 0.28 vs. 0.63 ± 0.35 PU·mmHg⁻¹; ΔCVC, pre-RIPC vs. 24 h; P < 0.05), but this change did not persist thereafter. Thus, 3QOD induced sustained improvement in endothelium-dependent vasodilation but was not sufficient to sustain increases in endothelium-independent vasodilation.

Keywords: laser speckle contrast imaging, skin blood flow, iontophoresis, local heating, endothelial dependent cutaneous vasodilation, endothelial independent cutaneous vasodilation, vascular adaptation, non-consecutive repeated remote ischemic preconditioning

Abbreviations: RIPC, remote ischemic preconditioning; CV, coefficient of variation; BMI, body mass index; CVC, cutaneous vascular conductance; MAP, mean arterial pressure; Ach, acetylcholine; SNP, sodium nitroprusside; VEGF, vascular endothelial growth factor; IR, ischemia-reperfusion; EDHF, endothelium-derived hyperpolarization factor; NO, nitric oxide; SOD, superoxide dismutase; 3QOD, 3 bouts of RIPC performed every other day.
INTRODUCTION

Ischemic heart disease and stroke are leading causes of death and have a high recurrence rate (Briffa et al., 2011; Benjamin et al., 2019). Regular moderate to high-intensity exercise training improves cardiovascular health and reduces cardiovascular disease incidence (Riebe et al., 2015). However, this intensity and frequency of exercise may not be practical in some clinical populations, such as those with severe ischemic heart disease or with limited mobility. Remote ischemic preconditioning (RIPC), consisting of three or four cycles of limb blood flow occlusion followed by reperfusion, may be an alternative intervention to improve cardiovascular function in these clinical populations. However, the threshold needed to elicit beneficial effects remains unclear. In the vasculature, a single bout of RIPC transiently increases endothelial function that peaks ~48 h after RIPC (Loukogeorgakis et al., 2005; Kim et al., 2021); however, this stimulus may not be sufficient to substantially improve clinical outcomes (Hausenloy et al., 2015; Meybohm et al., 2015).

Previous studies indicate that repeated bouts of RIPC confer additional and long-lasting vascular benefits (Thijsen et al., 2016; Lang et al., 2019). Repeated RIPC augments the brachial flow-mediated dilation response, an index of conduit artery endothelial function (Moro et al., 2011; van den Munckhof et al., 2013; Jones et al., 2014). In the microvasculature, we found that repeated RIPC (i.e., 12 bouts) improves cutaneous endothelium-dependent and endothelium-independent vasodilation, which is an indicator of vascular smooth muscle function (Kim et al., 2020). However, these 12 bouts of RIPC did not further augment cutaneous endothelium-dependent vasodilation beyond that seen with 7 bouts of RIPC (Kim et al., 2020), and the improvement in cutaneous microvascular function observed only after 7 bouts of RIPC persisted for a week (Lang et al., 2019). In contrast, a single bout of RIPC increased endothelium-dependent vasodilation during 24–48 h after a bout of RIPC, but this effect was not sustained for 72 h after a bout of RIPC, and endothelium-independent vasodilation was not affected (Kim et al., 2021). Collectively, these studies indicate that although a single bout of RIPC is sufficient to increase endothelium-dependent vasodilation, repeated bouts of RIPC are required to induce sustained improvement in endothelium-dependent and endothelium-independent vasodilation.

Using the skin circulation as a microvascular model (Holowatz et al., 2008; Khan et al., 2008; Minson, 2010), we tested whether 3 days of RIPC separated by rest days (3QOD RIPC) improves microvascular function and induces persistent functional augmentation. Administering RIPC during the peak of the window of improvement (i.e., 48 h after or every other day) elicited by the previous RIPC bout may further enhance the beneficial effects of RIPC. Thus, multiple RIPC on this delayed window phase may induce strong sustainable microvascular function augmentation with less repeated RIPC bouts. Therefore, we hypothesized that 3QOD RIPC will induce sustained augmentation in endothelium-dependent vasodilation, reflected by augmented cutaneous responses to local heating and Ach-mediated, and in endothelium-independent vasodilation to sodium nitroprusside (SNP) for a week after the last bout of RIPC.

MATERIALS AND METHODS

Subjects and Ethical Approval

Verbal and written informed consents were obtained from all participants before the experiments. The experiment procedure conformed to the standards set by the Declaration of Helsinki and was approved by the Institutional Review Board at Iowa State University (IRB# 19-482-00) and the Food and Drug Administration (FDA IND# 138343). A total of 13 healthy normotensive young subjects [aged 20.5 ± 3.9 years; 5 males, 8 females; mean arterial pressure (MAP) = 83.8 ± 6.0 mmHg; body mass index (BMI) = 22.9 ± 2.8 kg/m²] were involved in this study. Previous studies have shown that 13 participants were sufficient to see differences in RIPC-induced skin blood flow changes (Kim et al., 2020, 2021). Seven of eight female participants were taking birth control pills during the data collection period and the timing for their participation was not restricted. The one participant who was not taking birth control pills started the study while in the early follicular phase. All subjects were non-smokers, not obese according to BMI (<30 kg/m²), without a history of chronic skin diseases or skin allergies, and not taking medications or supplements that alter cardiovascular or thermoregulatory control.

Experimental Procedure

This study was designed to assess the temporal component of the skin blood flow responses following 3QOD RIPC. RIPC was elicited by 4 cycles for 5 min of arm cuff inflation to ~220 mmHg on the dominant arm, separated by 5 min of deflation. Arm blood flow was restricted by a pneumatic cuff (Rapid Cuff Inflation System, D.E. Hokanson, Inc., Bellevue, WA, United States) placed around the upper arm. Figure 1 shows a schematic of this study protocol. The first RIPC session was conducted immediately following the initial assessment of cutaneous microvascular function, and the next two sessions were conducted at 48 ± 2 h intervals. To test our hypothesis, we measured skin blood flow responses to local heating (Tloc = 42°C) and iontophoresis-mediated drug infusion to the arm contralateral to the ischemic arm. Skin blood flow measurements were repeated in the non-dominant arm five times over 7 days—immediately before the first RIPC bout and then 24 ± 2, 48 ± 2, 72 ± 2, and 168 ± 2 h (i.e., 1 week) after the last bout of RIPC.

On the days of the experiment, subjects were asked to fast (>3 h before coming to the laboratory), abstain from alcohol and caffeine (>12 h), and refrain from either novel or strenuous physical activity (24 h). Upon arrival at the laboratory (Ta = 23°C, RH = 18%), the participants rested on a bed in a semi-reclined position. Three electrodes were placed on the upper body to monitor heart rate continuously via a lead II electrocardiograph (CT-1000 cardiohctometer, CWE Inc., Ardmore, PA, United States). Blood pressure was measured every 10–15 min throughout the entire experimental protocol (Critikon 9300 Dinamap XL, Vital Signs Monitor, Temple, FL, United States).

Skin blood flow of the non-dominant forearm was assessed using laser speckle contrast imaging (LSCI) (Moors FLPI-2,
Moor Instruments, Axminster, United Kingdom). The LSCI imager was placed approximately 15–20 cm above the ventral surface of the forearm (wavelength = 785 nm, image exposure time = 4 ms, image acquisition rate = 25 frames/s). A vacuum cushion was placed underneath the measurement forearm to stabilize and minimize movement during image collection. After instrumentation was completed and resting hemodynamic data were collected, local heating and iontophoresis protocols began. The first RIPC session was conducted immediately after the initial assessment of cutaneous microvascular function, and the next two sessions were conducted at 48 ± 2 h intervals.

Laser Speckle Contrast Imaging
Laser speckle contrast imaging emits a beam of laser light that reflects off red blood cells as they move through skin vessels, thereby providing a non-invasive index of skin blood flow. It provides good to excellent day-to-day reproducibility; coefficient of variation (CV) for the local heating plateau is 15%, Ach peak is 19%, and SNP peak is 15% (Roustit et al., 2010; Tew et al., 2011; Mahe et al., 2012; Loader et al., 2017). Furthermore, we tested a group of participants (n = 8) who did not receive RIPC but underwent repeated local heating, Ach, and SNP measurements 2 weeks later, utilizing the same LSCI protocol. CVs were 7, 13, and 12%, respectively (local heating plateau: 1.93 ± 0.21 vs. 1.96 ± 0.17, Ach: 1.44 ± 0.2 vs. 1.44 ± 0.2, SNP: 1.14 ± 0.09 vs. 1.17 ± 0.14 PU-mmHg⁻¹). Thus, in our laboratory, our LSCI measurements with these perturbations have good to excellent reproducibility, thereby minimizing any effect that might occur due to chance.

Local Heating
A local heating unit (moor VHS-heat, Moor Instruments, Axminster, United Kingdom) was placed on the forearm skin surface >3 cm away from the antecubital fossa and filled with deionized water. A nickel-sized temperature controller was attached to the non-dominant forearm and maintained at a thermoneutral skin temperature (T_loc = 33°C or 91°F) during baseline. After collecting baseline measurements for ~10–15 min, the temperature of the controller was increased at a rate of 0.1°C/s to T_loc = 42°C and maintained for ~50 min until a stable plateau in the vasodilation response was achieved. Once the local heating procedure was started, the iontophoresis procedure began.

Iontophoresis
Iontophoresis was used to non-invasively administer Ach and SNP to test endothelium-dependent and endothelium-independent dilation, respectively. The active and indifferent electrodes were placed 5–10 cm apart on the skin surface of the measurement site. The active electrode was located at a separate skin site to prevent any current-related influence on the vasomotor function of the local heating site. Acetylcholine (Ach) and SNP were mixed with saline solution. To check non-drug-related responses, saline solution was administrated before each drug administration. When the local heating protocol began, saline solution was administrated via 20 µA anodal current for 200 s. After saline solution, 2% Ach solution, diluted in saline, was administrated with the same current intensity (20 µA anodal current for 200 s). After hyperemia resolved fully, the active electrode site was relocated to a 2-cm separated skin site and changed the polarity of iontophoresis. Saline solution was also administrated followed by a 1% SNP, diluted in saline, 20 µA cathodal current for 400 s. Those currents and duration were administrated in our previous studies and demonstrated a microvascular response without eliciting current-induced vasodilation (Kim et al., 2020, 2021).

Data Analysis
Laser speckle contrast imaging data were standardized as CVC, calculated as the mean LSCI flux (PU) divided by MAP (diastolic pressure + 1/3 pulse pressure), and expressed as PU-mmHg⁻¹. The baseline for all measurements (local heating-, Ach-, and SNP-induced vasodilatation) and the local heating plateau were averaged over a stable 2-min period. The initial peak of local heating and the peak responses to Ach and SNP were the means of
10 s of the highest flux value. Local heating-induced vasodilation, expressed as $\Delta$CVC, was calculated using (local heating plateau CVC–baseline CVC). Both Ach- and SNP-induced vasodilation were also expressed as $\Delta$CVC (Ach peak CVC–baseline CVC; SNP peak CVC–baseline CVC, respectively).

One-way repeated measure ANOVA (pre-RIPC vs. 24 h vs. 48 h vs. 72 h vs. 1 week after 3QOD RIPC as the main effect) was used to assess skin blood flow response changes to local heating, Ach, and SNP (SPSS version 26, IBM, Chicago, IL, United States). Fisher’s LSD post-hoc test was used to find significant differences between time points. Statistical significance was set at $\alpha = 0.05$. Skin blood flow data and subject characteristics are presented as mean ± SD.

RESULTS

Representative images from local heating ($T_{loc} = 42^\circ$C) and Ach- and SNP-induced cutaneous vasodilation responses throughout each measurement point (pre-RIPC, 24, 48, 72 h, and 1 week) are presented in Figure 2. The orange and red colors in Figure 2 represent skin blood flow augmentation.

Mean arterial pressure and local heating responses are provided in Table 1. It did not change throughout the five measurement visits ($P = 0.68$). Additionally, the CVC at baseline and the initial peak of the heating response did not change between measurement visits (baseline CVC, $P = 0.13$; initial peak CVC, $P = 0.42$). However, the local heating plateau and $\Delta$CVC changed after 3QOD RIPC (main effect, $P < 0.05$). The post-hoc test showed both local heating plateau and $\Delta$CVC tended to be increased 24 h after 3QOD RIPC (pre-RIPC vs. 24 h: heating plateau, $P = 0.054$; $\Delta$CVC, $P = 0.09$). After 72 h, RIPC increased at both the local heating-induced plateau and $\Delta$CVC at 72 h (pre-RIPC vs. 72 h: heating plateau, $P < 0.05$; $\Delta$CVC, $P < 0.05$) and tended to remain elevated for 1 week after the last day of 3QOD RIPC (pre-RIPC vs. 1 week: heating plateau, $P = 0.075$; $\Delta$CVC, $P = 0.054$).

Cutaneous responses to Ach and SNP iontophoresis are shown in Table 2. The main effect was not significant for either Ach- or SNP-induced $\Delta$CVC throughout the measurement points (main effect, $P = 0.22$), the Ach-induced peak CVC started to increase at 72 h (pre-RIPC vs. 72 h: $P = 0.06$), and both Ach-induced peak CVC and $\Delta$CVC significantly elevated for 1 week after the last day of 3QOD RIPC (pre-RIPC vs. 1 week: $P \leq 0.05$). The SNP-induced peak and $\Delta$CVC were also increased 24 h after 3QOD of RIPC (pre-RIPC vs. 24 h: $P < 0.05$) but returned to pre-RIPC in subsequent time points ($P > 0.05$).

The individual response in Ach-induced $\Delta$CVC between pre-RIPC and 1 week after 3QOD RIPC is shown in Figure 3A, and the individual response in SNP-induced $\Delta$CVC between

![](https://via.placeholder.com/150)
TABLE 1 | Local heating-mediated cutaneous vasodilation following 3 bouts of RIPC performed every other day.

|                  | Pre-RIPC | 24 h | 48 h | 72 h | 1 Week |
|------------------|----------|------|------|------|--------|
| MAP (mmHg)       | 83.8 ± 6.0 | 80.5 ± 7.2 | 81.2 ± 5.2 | 81.2 ± 6.5 | 81.5 ± 4.4 |
| Baseline CVC     | 0.41 ± 0.06 | 0.45 ± 0.09 | 0.43 ± 0.08 | 0.45 ± 0.06 | 0.41 ± 0.06 |
| Initial Peak     | 1.41 ± 0.32 | 1.54 ± 0.39 | 1.51 ± 0.26 | 1.55 ± 0.35 | 1.45 ± 0.31 |
| Heating plateau  | 1.49 ± 0.26 | 1.65 ± 0.32† | 1.60 ± 0.33 | 1.78 ± 0.48* | 1.62 ± 0.39† |
| Δ CVC            | 1.08 ± 0.24 | 1.20 ± 0.28† | 1.17 ± 0.31 | 1.34 ± 0.46* | 1.21 ± 0.36† |

Values are represented as cutaneous vascular conductance (PU·mmHg⁻¹); *P ≤ 0.05 vs. pre-RIPC, †P = 0.054 vs. pre-RIPC, ‡P ≤ 0.09 vs. pre-RIPC.

TABLE 2 | Acetylcholine- and sodium nitroprusside-mediated cutaneous vasodilation following 3 bouts of RIPC performed every other day.

|                  | Pre-RIPC | 24 h | 48 h | 72 h | 1 Week |
|------------------|----------|------|------|------|--------|
| Baseline CVC     | 0.46 ± 0.1 | 0.50 ± 0.1 | 0.49 ± 0.1 | 0.52 ± 0.1 | 0.52 ± 0.2 |
| Ach              | 0.55 ± 0.2 | 0.55 ± 0.1 | 0.54 ± 0.2 | 0.52 ± 0.1 | 0.55 ± 0.1 |
| SNP              | 1.20 ± 0.5 | 1.22 ± 0.5 | 1.30 ± 0.5 | 1.40 ± 0.4† | 1.46 ± 0.6* |
| Peak             | 1.01 ± 0.4 | 1.16 ± 0.4* | 1.04 ± 0.4 | 1.05 ± 0.3 | 1.15 ± 0.3 |
| Ach              | 0.73 ± 0.4 | 0.85 ± 0.5 | 0.82 ± 0.4 | 0.88 ± 0.3 | 0.96 ± 0.5* |
| SNP              | 0.47 ± 0.3 | 0.63 ± 0.3* | 0.52 ± 0.2 | 0.53 ± 0.2 | 0.61 ± 0.4 |

Values are represented as cutaneous vascular conductance (PU·mmHg⁻¹); *P < 0.05 vs. pre-RIPC, †P = 0.06 vs. pre-RIPC.

FIGURE 3 | Individ changes in CVC from baseline (ΔCVC·mmHg⁻¹) in response to Acetylcholine (A) between Pre-RIPC and a week after 3 days of RIPC, and sodium nitroprusside (B) between Pre-RIPC and 24 h after 3 days of RIPC. The red dashed lines represent participants that did not exhibit an increase in dilatory function. Group means ± SD are also shown. *p < 0.05 vs Pre-RIPC.

pre-RIPC and 24 h after 3QOD RIPC is shown in Figure 3B. For most participants (10 out of 13), Ach- and SNP-induced ΔCVC increased after 1 week and 24 h after 3QOD RIPC, respectively.

DISCUSSION

The purpose of this study was to test the extent to which 3QOD RIPC improves both endothelium-dependent and endothelium-independent cutaneous vasodilation and whether these changes persisted a week thereafter. The major findings were as follows: (1) 3QOD RIPC improved local heating-induced cutaneous vasodilation 72 h later, with the effect lasting 1 week; (2) Ach-induced cutaneous vasodilation increased and was significantly higher 1 week after 3QOD; and (3) SNP-mediated vasodilation was transiently increased 24 h before returning to baseline. These data suggest that 3QOD RIPC induced a delayed improvement in endothelium-dependent cutaneous vasodilation that persisted for at least 1 week. However, 3QOD was not sufficient to elicit lasting effects in the endothelium-independent vasodilation response.

A single bout of RIPC exhibits a characteristic delayed protective response that lasts for ∼24–72 h (Bolli et al., 2007). We have recently established that this delayed response also occurs in the human cutaneous microvasculature (Kim et al., 2021). During this phase, there is an increase in the synthesis of heat stress proteins (HSP 60 and HSP 72), superoxide dismutase (SOD), and inducible nitric oxide synthase (Marber et al., 1993; Yamashita et al., 1994; Wang et al., 2002; Doeppner et al., 2018), which may augment endothelial cell function (Bolli et al., 2007; Thijssen et al., 2016). In this study, the RIPC intervention was designed to stimulate the delayed phase by timing the implementation of subsequent RIPC sessions with the peak response (∼48 h) seen after the previous RIPC bout (Kim et al., 2021). Thus, perhaps
the third RIPC bout elicits a greater or more prolonged delayed window effect than what is typically observed after the first RIPC bout. Our findings support this notion in that 3QOD RIPC improved endothelium-dependent cutaneous vasodilation that persisted for a week.

Both local heating- and Ach-induced cutaneous vasodilation elicit endothelium-mediated dilation via nitric oxide (NO), endothelium-derived hyperpolarization factors (EDHF), and prostanooids (Noon et al., 1998; Kellogg et al., 1999, 2005; Durand et al., 2004; Minson, 2010; Brunt and Minson, 2012; Choi et al., 2014; Brunt et al., 2015). Both perturbations increase NO, which contributes to ∼50% of the total cutaneous vasodilation response (Fujii et al., 2013; Choi et al., 2014; Brunt et al., 2015; Greaney et al., 2019). Since NO is quickly inactivated with oxidative stress (Lobo et al., 2010), the elevated SOD level (Monk et al., 1989) during the delayed phase following RIPC may protect eNOS and elevate NO bioavailability. Furthermore, elevated NO bioavailability directly induces endothelium-dependent cutaneous vasodilation and stimulates K_{ATP} channels that induced EDHF-mediated vasodilation (Fujii et al., 2020). However, our previous study has shown that 7 consecutive days of RIPC did not improve NO contribution on local heating cutaneous vasodilation even after 1 week of the last bout of RIPC (Lang et al., 2019). Therefore, NO bioavailability elevations in the delayed window may contribute to prolonged endothelium-dependent cutaneous vasodilation improvements by stimulating EDHF via K_{ATP} channels (Fujii et al., 2020). This is supported by animals studies showing that the activity of biosynthetic enzymes for hydrogen sulfide increases during the delayed window (Wang et al., 2021).

Although both local heating and Ach-mediated dilation were increased following 3QOD RIPC, the increase in the timing of their CVC differed. Ach elicited more gradual improvements in the dilation response through the measurement periods that reached significance 1-week post-RIPC. This may be explained by our method of Ach administration and the lower drug concentration that was used. Higher doses of Ach (≥10 mM) administered by intradermal microdialysis showed a greater EDHF contribution to the vasodilation response (Brunt et al., 2015). Therefore, it is possible that our Ach concentration may not be robust enough to stimulate EDHF throughout the measurement points. In contrast, EDHF strongly contributes to local heating-mediated vasodilation (Brunt and Minson, 2012; Choi et al., 2014; Brunt et al., 2015), which showed an earlier and more robust increase following 3QOD RIPC. However, further study is required to confirm the role of EDHF on the effects of repeated RIPC.

Endothelium-independent cutaneous vasodilation may be explained by vascular smooth muscle sensitivity to NO or angiogenesis. NO activates myosin light chain phosphatase via cyclic guanosine monophosphate (cGMP) and induces smooth muscle relaxation. A previous study has shown circulating cGMP level augmentation after ischemic preconditioning on an animal in vivo heart (Iliodromitis et al., 1996). In humans, vascular endothelial growth factors (VEGF) and endothelial progenitor cells contribute to new blood vessel formation following 4 weeks of repeated RIPC (Kimura et al., 2007). Furthermore, we showed that 2 weeks of repeated RIPC improved endothelium-independent cutaneous vasodilation (Kim et al., 2020). Therefore, we hypothesized that 3QOD RIPC may also augment the endothelium-independent vasodilation response; however, we observed an increase in the endothelium-independent vasodilation 24 h after 3QOD RIPC that did not persist for a week. These results suggested that 3QOD RIPC may transiently improve vascular smooth muscle sensitivity but may not be sufficient enough to elicit cutaneous microvascular angiogenesis.

Multiple repeated RIPC studies have used different intervention durations, ranging from 1 to 8 weeks (Kimura et al., 2007; Jones et al., 2014, 2015; Lang et al., 2019; Kim et al., 2020). One of the collective findings from these studies was that longer durations of RIPC intervention did not elicit greater local heating-mediated endothelium-dependent cutaneous vasodilation (Jones et al., 2015; Kim et al., 2020). We extended these findings to demonstrate that 3QOD RIPC bouts were sufficient to elicit lasting improvement in the local heating-mediated dilation response. Furthermore, since a single bout of RIPC elicits a characteristic delayed response (Kim et al., 2021), the pattern of when RIPC is administered may also influence cutaneous microvascular function. From a clinical perspective, it is important to know the intervention duration and frequency needed to elicit sustained responses to optimize the beneficial or protective effects of RIPC without unnecessary pain to the clinical population.

**Limitations**

Although 3QOD RIPC statistically improved endothelium-mediated cutaneous vasodilation, a few of the participants did not respond in this manner (i.e., 3 out of 13 subjects—1 male, 2 females, Figure 3). Since 3QOD RIPC bouts spanned only a week, the individual response pattern may vary due to individual characteristics such as sex, physical fitness level, and blood lipid level (Trachte et al., 2020). Our sample size was not large enough to detect differences based on these characteristics. Regarding sex, there were more women (n = 8) than men (n = 5) in the study, which may affect the generalizability of the results in this study. However, neither this study nor the previous studies examining the effects of RIPC in skin circulation have suggested that sex differences in vascular reactivity occur (Deschênes et al., 2016; Lang et al., 2019; Kim et al., 2020, 2021). Thus, data in men and women were pooled in this current study for analysis. Finally, this study did not have a time control group. However, we previously measured interday reproducibility of skin blood flow responses to local heating, Ach, and SNP with LSCI. Our skin blood flow measurement with LSCI showed good reproducibility (C.V. < 13%) compared with previous studies (C.V. < 30%) (Tew et al., 2011; Mahe et al., 2012). Thus, our current data are reliable to confirm our results.

**CONCLUSION**

Compared with a single bout of RIPC, as shown in our previous study (Kim et al., 2021), 3QOD elicits more sustained...
improvement in microvascular function. 3QOD RIPC induced delayed endothelium-dependent cutaneous vasodilation, and this improvement remained elevated for 1 week after the last RIPC bout. However, endothelium-independent vasodilation was transiently elevated for 24 h after RIPC and did not persist. Our findings indicate that repeated RIPC administered every other day, which corresponds to the peak of the delayed phase, induces more sustained endothelium-mediated function improvements. This suggests that an every other day RIPC protocol may optimize endothelial function, and more RIPC bouts are needed to elicit cutaneous microvascular structural changes.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Iowa State University Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

JK, WF, and JL contributed to the conception and design of the study, interpreted the data, and edited and revised the manuscript. JK collected and analyzed data, and drafted the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was funded by the Iowa State University.

ACKNOWLEDGMENTS

We thank the study participants for their participation. We especially thank Sydney Barlow and Kelsey Schwartz for their assistance on this study project.

REFERENCES

Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., et al. (2019). Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 139:e56.

Bolli, R., Li, Q. H., Tang, X. L., Guo, Y., Xuan, Y. T., Rokosh, G., et al. (2007). The late phase of preconditioning and its natural clinical application - gene therapy. Heart Fail. Rev. 12, 189–199. doi: 10.1007/s10741-007-9031-4

Briffa, T. G., Hobbs, M. S., Tonkin, A., Sanfilippo, F. M., Hickling, S., Ridout, S. C., et al. (2011). Population trends of recurrent coronary heart disease event rates remain high. Circ. Cardiovasc. Qual. Outcomes 4, 107–113. doi: 10.1161/CIRCOUTCOMES.110.957944

Brunt, V. E., Fujii, N., and Minson, C. T. (2015). Endothelial-derived hyperpolarization contributes to acetylcholine-mediated vasodilation in human skin in a dose-dependent manner. J. Appl. Physiol. 119, 1015–1022. doi: 10.1152/japplphysiol00201.2015

Brunt, V. E., and Minson, C. T. (2012). KCa channels and epoxyeicosatrienoic acids: major contributors to thermal hyperaemia in human skin. J. Physiol. 590, 3523–3534. doi: 10.1113/jphysiol.2012.236398

Choi, P. J., Brunt, V. E., Fujii, N., and Minson, C. T. (2014). New approach to measure cutaneous microvascular function: an improved test of NO-mediated vasodilation by thermal hyperemia. J. Appl. Physiol. 117, 277–283. doi: 10.1152/japplphysiol.01397.2013

Descênes, P. P., Joanisse, D. R., and Billaud, F. (2016). Sex-Specific Impact of Ischemic Preconditioning on Tissue Oxygenation and Maximal Concentric Force. Front. Physiol. 7:674–674. doi: 10.3389/fphys.2016.00674

Doeppner, T. R., Zecheleimer, B., Kaltwasser, B., Jin, F., Zheng, X., Majid, A., et al. (2018). Very Delayed Remote Ischemic Post-conditioning Induces Sustained Neurological Recovery by Mechanisms Involving Enhanced Angioneurogenesis and Peripheral Immunosuppression Reversal. Front. Cell Neurosci. 12:383. doi: 10.3389/fncel.2018.00383.

Durand, S., Tartas, M., Bousé, P., Koitka, A., Saumet, J. L., and Abraham, P. (2004). Prostaglandins participate in the late phase of the vascular response to acetylcholine iontophoresis in humans. J. Physiol. 561, 811–819. doi: 10.1113/jphysiol.2004.069997

Fujii, N., McGarr, G. W., Kenny, G. P., Amano, T., Honda, Y., Kondo, N., et al. (2020). NO-mediated activation of K-ATP channels contributes to cutaneous thermal hyperemia in young adults. Am. J. Physiol. Regul. Integr. Comp. Physiol. 318, R390–R398. doi: 10.1152/ajpregu.00176.2019

Fuji, N., Reinke, M. C., Brunt, V. E., and Minson, C. T. (2013). Impaired acetylcholine-induced cutaneous vasodilation in young smokers: roles of nitric oxide and prostanooids. Am. J. Physiol. Heart Circ. Physiol. 304, H667–H673. doi: 10.1152/ajpheart.00731.2012

Greaney, J. L., Saunders, E. F. H., Santhamam, L., and Alexander, L. M. (2019). Oxidative Stress Contributes to Microvascular Endothelial Dysfunction in Men and Women With Major Depressive Disorder. Circ. Res. 124, 564–574. doi: 10.1161/CIRCRESAHA.118.313764

Hausenloy, D. J., Candilio, L., Evans, R., Kolvekar, S., Ariti, C., Jenkins, D. P., et al. (2015). Remote ischemic preconditioning and outcomes of cardiac surgery. N. Engl. J. Med. 373, 1408–1417.

Holowatz, L. A., Thompson-Torgerson, C. S., and Kenney, W. L. (2008). The human cutaneous circulation as a model of a generalized microvascular function. J. Appl. Physiol. 105, 370–372.

Iliodromitis, E. K., Papadopoulos, C. C., Markianos, M., Parasekevadis, I. A., Kyriakides, Z. S., and Kremastinos, D. T. (1996). Alterations in circulating cyclic guanosine monophosphate (c-GMP) during short and long ischemia in preconditioning. Basic Res. Cardiol. 91, 234–259. doi: 10.1007/BF00788909

Jones, H., Hopkins, N., Bailey, T. G., Green, D. J., Cable, N. T., and Thijssen, D. H. J. (2014). Seven-Day Remote Ischemic Preconditioning Improves Local and Systemic Endothelial Function and Microcirculation in Healthy Humans. Am. J. Hypertens 27, 918–925. doi: 10.1093/ajh/hpu004

Jones, H., Nyakayiru, J., Bailey, T. G., Green, D. J., Cable, N. T., Sprung, V. S., et al. (2015). Impact of eight weeks of repeated ischemic preconditioning on brachial artery and cutaneous microcirculatory function in healthy males. Eur. J. Prev. Cardiol. 22, 1083–1087. doi: 10.1177/2047487314547657

Kellgren, D. L., Liu, Y., Kosiba, I. F., and O’Donnell, D. (1999). Role of nitric oxide in the vascular effects of local warming of the skin in humans. J. Appl. Physiol. 86, 1185–1190. doi: 10.1152/jappl.1999.86.4.1185

Kellgren, D. L., Zhao, J., Coey, U., and Green, J. (2005). Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin. J. Appl. Physiol. 98, 629–632. doi: 10.1152/japplphysiol.00728.2004

Khan, F., Patterson, D., Belch, J. J. F., Hirata, K., and Lang, C. C. (2008). Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography. Clin. Sci. 115, 295–300. doi: 10.1042/CS20070431

Kim, J., Franke, W. D., and Lang, J. A. (2020). Improved endothelial-dependent and endothelial-independent skin vasodilator responses following remote ischemic

AUTHOR CONTRIBUTIONS

JK, WF, and JL contributed to the conception and design of the study, interpreted the data, and edited and revised the manuscript. JK collected and analyzed data, and drafted the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was funded by the Iowa State University.
Kim, J., Franke, W. D., and Lang, J. A. (2021). Delayed window of improvements following a single bout of remote ischemic preconditioning. *Exp. Physiol.* 106, 1380–1388. doi: 10.1113/EP089438

Kimura, M., Ueda, K., Goto, C., Jitsuiki, D., Nishioka, K., Umemura, T., et al. (2007). Repetition of ischemic preconditioning augments endothelium-dependent vasodilation in humans - Role of endothelium-derived nitric oxide and endothelial progenitor cells. *Arterioscler Thromb Vasc Biol.* 27, 1403–1410. doi: 10.1161/ATVBAHA.107.143578

Lang, J. A., Kim, J., Franke, W. D., and Vianna, L. C. (2019). Seven consecutive days of remote ischemic preconditioning improves cutaneous vasodilatory capacity in young adults. *J. Physiol.* 597, 757–767. doi: 10.1113/JP277185

Loader, J., Roustit, M., Taylor, F., Macisaac, R. J., Stewart, S., Lorenzen, C., et al. (2010). Assessing cutaneous microvascular function with iontophoresis: Avoiding non-specific vasodilation. *Microvasc. Res.* 83, 29–39. doi: 10.1016/j.mvr.2017.04.006

Lobo, V., Patil, A., Phatak, A., and Chandra, N. (2010). Free radicals, antioxidants and functional foods: Impact on human health. *Pharmacogn. Rev.* 4, 118–126. doi: 10.4103/0973-7847.70902

Loukogeorgakis, S. P., Panagiotidou, A. T., Broadhead, M. W., Donald, A., Deanfield, J. E., and Macallister, R. J. (2005). Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system: role of the autonomic nervous system. *J. Am. Coll. Cardiol.* 46, 450–456. doi: 10.1016/j.jacc.2005.04.044

Mahe, G., Humeau-Heurtier, A., Durand, S., Leftheriotis, G., and Abraham, P. (2012). Assessment of skin microvascular function and dysfunction with laser speckle contrast imaging. *Circ. Cardiovasc. Imaging* 5, 155–163. doi: 10.1161/CIRCIMAGING.111.970418

Marber, M. S., Latchman, D. S., Walker, J. M., and Yellow, D. M. (1993). Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. *Circulation* 88, 1264–1272. doi: 10.1161/01.cir.88.3.1264

Meybohm, P., Bein, B., Brosteaua, O., Cremer, J., Gruenewald, M., Stoppe, C., et al. (2015). A multicenter trial of remote ischemic preconditioning for heart surgery. *N. Engl. J. Med.* 373, 1397–1407. doi: 10.1056/NEJMoa1413579

Minson, C. T. (2010). Thermal provocation to evaluate microvascular reactivity in human skin. *J. Appl. Physiol.* 109, 1239–1246. doi: 10.1152/japplphysiol.00414.2010

Monk, L. S., Fagerstedt, K. V., and Crawford, M. M. (1989). Oxygen toxicity and cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. *Br. J. Clin. Pharmacol.* 45, 545–550. doi: 10.1046/j.1365-2125.1998.00718.x

Riebe, D., Franklin, B. A., Thompson, P. D., Garber, C. E., Whitfield, G. P., Magal, M., et al. (2015). Updating ACSM’s recommendations for exercise preparticipation health screening. *Med. Sci. Sports Exerc.* 47, 2473–2479. doi: 10.1249/MSS.0000000000000664

Roustit, M., Millet, C., Blaise, S., Dufournet, B., and Cracowski, J. L. (2010). Excellent reproducibility of laser speckle contrast imaging to assess skin microvascular reactivity. *Microvasc. Res.* 80, 505–511. doi: 10.1016/j.mvr.2010.05.012

Tew, G. A., Klonizakis, M., Cranke, H., Briers, J. D., and Hodges, G. J. (2011). Comparison of laser speckle contrast imaging with laser Doppler for assessing microvascular function. *Microvasc. Res.* 82, 326–332. doi: 10.1016/j.mvr.2011.07.007

Thijssen, D. H. J., Maxwell, J., Green, D. J., Cable, N. T., and Jones, H. (2016). Repeated ischemic preconditioning: a novel therapeutic intervention and potential underlying mechanisms. *Exp. Physiol.* 101, 677–692. doi: 10.1113/EP085566

Trachte, T. E., Hemenway, B. A., and Van Guider, G. P. (2020). Reduced effect of ischemic preconditioning against endothelial ischemia-reperfusion injury with cardiovascular risk factors in humans. *J. Hum. Hypertens* 35,870–879 doi: 10.1038/s41371-020-00440-0

van den Munckhof, I., Riksen, N., Seeger, J. P. H., Schreuder, T. H., Borm, G. F., Eijsvogels, T. M. H., et al. (2013). Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemia-reperfusion injury in humans. *Am. J. Physiol. Heart Circ. Physiol.* 304, H1727–H1732. doi: 10.1152/ajpheart.00054.2013

Wang, H., Shi, X., Chen, L., Han, J., and Mu, J. (2021). Hydrogen sulfide restores cardioprotective effects of remote ischemic preconditioning in aged rats. *Korean J. Physiol. Pharmacol.* 25, 239–249. doi: 10.4196/kjpp.2021.25.3.239

Wang, Y., Guo, Y., Zhang, S., Wu, W., Wang, J., Bao, W., et al. (2002). Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocytes. *J. Mol. Cell Cardiol.* 34, 5–15.

Yamashita, N., Nishida, M., Hoshida, S., Kuzuya, T., Hori, M., Taniguchi, N., et al. (2013). Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemia-reperfusion injury in humans. *Circ. Res.* 112, 1933–1944. doi: 10.1161/CIRCRESAHA.112.294554

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Kim, Franke and Lang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.